Investors might want to bet on MAIA Biotechnology, Inc. (MAIA), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

THIO has gained its generic name and preclinical data on a different form of the cancer drug suggests it could improve ...

MAIA Biotechnology (MAIA) announced the publication of preclinical data for its lead proprietary telomere-targeting THIO dimer in the ...

MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract ...

MAIA Biotechnology receives USAN Council approval for “ateganosine” as nonproprietary name for anticancer agent THIO: Chicago Friday, March 21, 2025, 14:00 Hrs [IST] MAIA Biot ...

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing ...

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing ...

10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in ...

MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug ...

MAIA Biotechnology (MAIA) announced that the United States Adopted Names Council has approved “ateganosine” as the nonproprietary name for its ...